Opthea Ltd. is engaged in developing biological therapeutics for cancer and other serious diseases. It is a biologics drug developer building on its significant intellectual property portfolio around Vascular Endothelial Growth Factor C and D angiogenic molecules and R3. The company focuses on vascular endothelial growth factors to develop truly novel therapies to extend and improve the lives of cancer sufferers. Opthea was founded on October 17, 1984 and is headquartered in South Yarra, Australia.
|Market Price at 20-11-2017||$0.70|
|Price to Earnings Ratio||-19.54|
|Market Capitalisation||$140.40 (million)|
|Return on Equity (ROE)||-11.36%|